Health ImprOvement Program of Bone in China

Second Xiangya Hospital of Central South University1 site in 1 country5,000 target enrollmentFebruary 27, 2021

ConditionsOsteoporosis

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Osteoporosis
Sponsor: Second Xiangya Hospital of Central South University
Enrollment: 5000
Locations: 1
Primary Endpoint: clinical risk factors of osteoporotic fracture
Status: Recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Fracture risk factors have long been identified as key factors in osteoporosis and fragility fractures. The WHO recommended Fracture risk assessmenttool (FRAX) applies clinical risk factors to assess the absolute risk of osteoporotic fractures in each individual. Our preliminary study suggests that FRAX estimates may underestimate the risk of fractures in the Chinese population. In order to optimize the risk prediction model of osteoporotic fractures, a treatment threshold and its optimal cutting point were initially established based on the data of the health management Center of the Second Xiangya Hospital of Central South University.

Registry

clinicaltrials.gov

Start Date

February 27, 2021

End Date

February 27, 2031

Last Updated

2 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Second Xiangya Hospital of Central South University

Responsible Party

Principal Investigator

sheng zhifeng

Director of the Health Management Center of the Second Xiangya Hospital of Central South University

Second Xiangya Hospital of Central South University

Eligibility Criteria

Inclusion Criteria

•Dual-energy X-ray bone mineral density measurement was performed in the health management center of our hospital in the physical examination subjects over 40 years old. Have independent civil capacity and agree to participate, and sign informed consent

Exclusion Criteria

•Under 40 years of age， Patients who had undergone hip replacement or lumbar surgery and could not perform dual-energy X-ray BMD testing; Patients who have been treated with effective anti-osteoporosis drugs or have a history of malignant tumors.